These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36527386)

  • 21. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
    Ono R; Furihata K; Ichikawa Y; Nakazuru Y; Bergman A; Gorman DN; Saxena AR
    Diabetes Obes Metab; 2023 Mar; 25(3):805-814. PubMed ID: 36433713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
    Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
    BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.
    Di Prospero NA; Yee J; Frustaci ME; Samtani MN; Alba M; Fleck P
    Clin Obes; 2021 Apr; 11(2):e12433. PubMed ID: 33475251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
    Ji L; Jiang H; Cheng Z; Qiu W; Liao L; Zhang Y; Li X; Pang S; Zhang L; Chen L; Yang T; Li Y; Qu S; Wen J; Gu J; Deng H; Wang Y; Li L; Han-Zhang H; Ma Q; Qian L
    Nat Commun; 2023 Dec; 14(1):8289. PubMed ID: 38092790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.
    Alba M; Yee J; Frustaci ME; Samtani MN; Fleck P
    Clin Obes; 2021 Apr; 11(2):e12432. PubMed ID: 33475255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
    Ratner R; Nauck M; Kapitza C; Asnaghi V; Boldrin M; Balena R
    Diabet Med; 2010 May; 27(5):556-62. PubMed ID: 20536952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
    Ambery PD; Klammt S; Posch MG; Petrone M; Pu W; Rondinone C; Jermutus L; Hirshberg B
    Br J Clin Pharmacol; 2018 Oct; 84(10):2325-2335. PubMed ID: 29926478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.
    Eriksson O; Haack T; Hijazi Y; Teichert L; Tavernier V; Laitinen I; Berglund JE; Antoni G; Velikyan I; Johansson L; Pierrou S; Wagner M; Tillner J
    Sci Rep; 2020 Oct; 10(1):16758. PubMed ID: 33028880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
    Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
    Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.